MedWatch

Logistics and comparisons will bring growth down for Ambu, analyst says

Senior analyst at Sydbank Søren Løntoft Hansen has subdued expectations for the first quarter of medtech company Ambu.

Photo: Ambu / PR

The first quarter for the skewed 2021/2022 financial year will be marked by a difficult basis of comparison and continued logistical challenges, both of which will put a damper on the report, says Søren Løntoft Hansen, senior equity analyst at Danish bank Sydbank, prior to the report’s release on February 8.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs